Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Alexander, Parkhomenko"'
Autor:
John H Alexander, Christopher B Granger, Sigrun Halvorsen, Stephan Windecker, Dragos Vinereanu, Daniel M Wojdyla, Roxana Mehran, Shaun Goodman, Renato Lopes, Robert C. Welsh, Payam Dehghani, Ronald Aronson, Amit N Vora, Alexander Parkhomenko
Publikováno v:
Open Heart, Vol 9, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/df9d747ec8bc46c0a31fa9a683c18973
Autor:
Giulia Magnani, Diego Ardissino, KyungAh Im, Andrzej Budaj, Robert F. Storey, P. Gabriel Steg, Deepak L. Bhatt, Marc Cohen, Ton Oude Ophius, Assen Goudev, Alexander Parkhomenko, Gabriel Kamensky, Dominick J. Angiolillo, José López‐Sendón, Per Johanson, Eugene Braunwald, Marc S. Sabatine, Marc P. Bonaca
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 4 (2021)
Background Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction. Identification of patients at lower bleeding risk is important in selecting patients who are likely to derive more favorable outcomes ver
Externí odkaz:
https://doaj.org/article/380c3bd2158546a98fc3e85a0f10d67e
Autor:
Ziad Hijazi, Christopher B. Granger, Stefan H. Hohnloser, Johan Westerbergh, Johan Lindbäck, John H. Alexander, Matyas Keltai, Alexander Parkhomenko, José L. López-Sendón, Renato D. Lopes, Agneta Siegbahn, Lars Wallentin
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 18 (2020)
Background We compared different methods of estimated glomerular filtration rate (eGFR) and their association with cardiovascular death and major bleeding in 14 980 patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke
Externí odkaz:
https://doaj.org/article/c55f0fc3f82c42adaf15cbcb564747c9
Autor:
Zoltán Papp, Piergiuseppe Agostoni, Julian Alvarez, Dominique Bettex, Stefan Bouchez, Dulce Brito, Vladimir Černý, Josep Comin-Colet, Marisa G Crespo-Leiro, Juan F Delgado, Istvan Édes, Alexander A Eremenko, Dimitrios Farmakis, Francesco Fedele, Cândida Fonseca, Sonja Fruhwald, Massimo Girardis, Fabio Guarracino, Veli-Pekka Harjola, Matthias Heringlake, Antoine Herpain, Leo MA Heunks, Tryggve Husebye, Višnja Ivancan, Kristjan Karason, Sundeep Kaul, Matti Kivikko, Janek Kubica, Josep Masip, Simon Matskeplishvili, Alexandre Mebazaa, Markku S Nieminen, Fabrizio Oliva, Julius-Gyula Papp, John Parissis, Alexander Parkhomenko, Pentti Põder, Gerhard Pölzl, Alexander Reinecke, Sven-Erik Ricksten, Hynek Riha, Alain Rudiger, Toni Sarapohja, Robert HG Schwinger, Wolfgang Toller, Luigi Tritapepe, Carsten Tschöpe, Gerhard Wikström, Dirk von Lewinski, Bojan Vrtovec, Piero Pollesello
Publikováno v:
Cardiac Failure Review, Vol 6, Iss , Pp e19- (2020)
Externí odkaz:
https://doaj.org/article/e824d2a9b806462bbcee54e624465f55
Autor:
Alexander Parkhomenko
Publikováno v:
Circulation. 147:779-781
Autor:
Warren J. Cantor, Mary Tan, Otavio Berwanger, Shahar Lavi, Harvey D. White, Jose C. Nicolau, Payam Dehghani, Carlos D. Tajer, Renato D. Lopes, Diogo D.F. Moia, Stephen J. Nicholls, Alexander Parkhomenko, Oleg Averkov, Neil Brass, Sohrab Lutchmedial, Germán Malaga, Lucas P. Damiani, Leopoldo S. Piegas, Christopher B. Granger, Shaun G. Goodman
Publikováno v:
American Heart Journal. 251:1-12
Background: Morphine is commonly used to relieve pain, anxiety and dyspnea in STEMI but it lowers blood pressure and delays the activity of oral antiplatelet agents. The impact of morphine on clinical outcomes remains unknown. This analysis was perfo
Autor:
Marc P. Bonaca, Stephen D. Wiviott, David A. Morrow, P. Gabriel Steg, Christian Hamm, Deepak L. Bhatt, Robert F. Storey, Marc Cohen, Julia Kuder, KyungAh Im, Giulia Magnani, Andrzej Budaj, José C. Nicolau, Alexander Parkhomenko, José López‐Sendón, Mikael Dellborg, Rafael Diaz, Frans Van de Werf, Ramón Corbalán, Assen Goudev, Eva C. Jensen, Per Johanson, Eugene Braunwald, Marc S. Sabatine
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 22 (2018)
Background Ticagrelor reduced cardiovascular death, myocardial infarction (MI), or stroke in patients with prior MI in PEGASUS‐TIMI 54 (Prevention of Cardiovascular Events [eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patie
Externí odkaz:
https://doaj.org/article/03874c11a1de44acb9223300b968ce86
Autor:
Piero Pollesello, Tuvia Ben Gal, Dominique Bettex, Vladimir Cerny, Josep Comin-Colet, Alexandr A. Eremenko, Dimitrios Farmakis, Francesco Fedele, Cândida Fonseca, Veli-Pekka Harjola, Antoine Herpain, Matthias Heringlake, Leo Heunks, Trygve Husebye, Visnja Ivancan, Kristian Karason, Sundeep Kaul, Jacek Kubica, Alexandre Mebazaa, Henning Mølgaard, John Parissis, Alexander Parkhomenko, Pentti Põder, Gerhard Pölzl, Bojan Vrtovec, Mehmet B. Yilmaz, Zoltan Papp
Publikováno v:
Journal of Clinical Medicine, Vol 8, Iss 11, p 1834 (2019)
Both acute and advanced heart failure are an increasing threat in term of survival, quality of life and socio-economical burdens. Paradoxically, the use of successful treatments for chronic heart failure can prolong life but—per definition—causes
Externí odkaz:
https://doaj.org/article/1b7fa2019da64cc39472084bea848f06
Autor:
Batric Popovic, Gregory Ducrocq, Yedid Elbez, Christoph Bode, Shamir. R. Mehta, Charles V. Pollack, Manel Sabate, Sunil V. Rao, Alexander Parkhomenko, Laurent J. Feldman, Neila Sayah, Marc S. Sabatine, Philippe Gabriel Steg
Publikováno v:
The American journal of cardiology. 188
In patients with non-ST-elevation myocardial infarction (NSTEMI), total occlusion of the culprit coronary artery (OCA) is not uncommon. We sought to determine the frequency and clinical impact of OCA at presentation in a large population of patients
Autor:
Renato D. Lopes, M. Cecilia Bahit, Stephan Windecker, Peter Sinnaeve, Daniel Wojdyla, Ziad Hijazi, Sigrun Halvorsen, Harald Darius, Alexander Parkhomenko, Otávio Berwanger, Robert F. Storey, Zhuokai Li, Roxana Mehran, John H. Alexander, Ronald Aronson, Suzanne de Waha-Thiele, Christopher B. Granger
Publikováno v:
Circulation. 143:1215-1223
Background: In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute C